Factory Supply CAS 877399-52-5 Crizotinib Anticancer Crizotinib

Crizotinib High Purity Powder

Crizotinib is a substance with antitumor effects, belonging to the class of targeted therapeutic drugs. At room temperature, it usually appears as a white to pale yellow powder, odorless, easily soluble in dimethyl sulfoxide and poorly soluble in water. This substance inhibits the growth and proliferation of tumor cells by suppressing the activity of specific tyrosine kinases and blocking the signal transduction pathways of tumor cells. Clinically, it is commonly used to treat locally advanced or metastatic non-small cell lung cancer with specific gene mutations (such as ALK fusion gene, ROS1 fusion gene) to control tumor progression and improve patients' symptoms.

Crizotinib is an oral small-molecule tyrosine kinase inhibitor (TKI), primarily used for the treatment of non-small cell lung cancer (NSCLC) harboring specific gene mutations or fusions, belonging to precision targeted therapy drugs. It exerts its effects by specifically inhibiting the activity of anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), and c-MET proto-oncogene (MET). This blocks the tumor cell signaling pathways mediated by these targets, inhibiting the proliferation, survival, and metastasis of tumor cells, thereby controlling tumor progression. In clinical practice, it is mainly used to treat ALK-positive locally advanced or metastatic NSCLC, as well as ROS1-positive advanced NSCLC. It can significantly prolong patients' progression-free survival, alleviate tumor-related symptoms such as cough, chest pain, and dyspnea, and improve patients' quality of life. In addition, it is well absorbed orally and can cross the blood-brain barrier, providing a certain therapeutic effect for NSCLC patients with brain metastases.

Certificate of Analysis